港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

科伦博泰生物-B

285.400

-3.600-1.25%

成交量：81.19万

成交额：2.33亿

市值：647.86亿

市盈率：-222.78

高：294.000

开：285.000

低：275.000

收：289.000

数据加载中...

总览公司新闻公告

《大行》招银国际下调科伦博泰(06990.HK)目标价至227.88元评级“买入”

阿斯达克财经

招银国际：维持科伦博泰生物-B(06990)“买入”评级目标价227.88港元

智通财经网

国金证券：市场对医药左侧反转的重视上升呼吸道感染上行关注相关板块

和铂医药(02142.HK)科伦博泰(06990.HK)联合开发产品WIN378授出独家许可

阿斯达克财经

科伦博泰生物-B与Windward Bio AG就SKB378/HBM9378订立独占性许可协议

和铂医药-B(02142)及科伦博泰(06990)与WINDWARD BIO AG就HBM9378/SKB378订立独家授权协议

招银国际：政策持续发力看好中国医药估值反弹

【券商聚焦】招银国际指医药行业受益于海外降息以及国内宏观环境改善有望在2025年跑赢市场

科伦博泰生物(06990.HK)核心产品博度曲妥珠单抗新药申请获受理

阿斯达克财经

科伦博泰生物-B(06990)：核心产品博度曲妥珠单抗的新药申请获国家药监局受理

国联证券2025年医药生物投资策略：增量看空间存量看结构

国金证券：重磅政策出炉创新仍是最重要方向医药健康行业进入业绩窗口关注反转预期

异动解读 | 注射液上市获批科伦博泰生物-B盘中大涨5%

科伦博泰生物-B盘中异动早盘股价大涨5.02%

【港股通】科伦博泰生物-B逆市升逾4% 抗PD-L1塔戈利单抗获国家药监局批准上市

【港股异动 | 科伦博泰生物-B(06990.HK)现涨超4% 】科伦博泰生物-B(06990.HK)早盘涨超4%，截至发稿，涨4.53%，报170.7港元，成交额944.08万港元。

港股异动 | 科伦博泰生物-B(06990)现涨超4% 国家药监局批准塔戈利单抗注射液上市

年度盘点｜2024年的港股医药生物公司跌多涨少，涨跌幅最大前十公司分别有何共性

全球首款CLDN18.2靶向药国内获批上市，热门靶点竞争格局几何

科伦博泰(06990.HK)抗PD-L1塔戈利单抗获国家药监局批准上市

阿斯达克财经

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/06990/news?page=7"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06990","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","market":"HK","secType":"STK","nameCN":"科伦博泰生物-B","latestPrice":285.4,"timestamp":1744877289037,"preClose":289,"halted":0,"volume":811904,"delay":0,"floatShares":131000000,"shares":227000000,"eps":-1.2811130563505986,"marketStatus":"复活节星期一休市","change":-3.6,"latestTime":"04-17 16:08:09","open":285,"high":294,"low":275,"amount":232778521,"amplitude":0.065744,"askPrice":286.4,"askSize":300,"bidPrice":285.4,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-1.2811130563505986,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1745285400000},"marketStatusCode":7,"adr":0,"listingDate":1689004800000,"exchange":"SEHK","adjPreClose":289,"openAndCloseTimeList":[[1744853400000,1744862400000],[1744866000000,1744876800000]],"volumeRatio":1.0355934219983844,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06990\",,,,,undefined,":{"symbol":"06990","floatShares":131000000,"roa":"-3.41%","roe":"-9.46%","lyrEps":-1.281113,"volumeRatio":1.0355934219983844,"shares":227000000,"dividePrice":0,"high":294,"amplitude":0.065744,"preClose":289,"low":275,"week52Low":120.2,"pbRate":"18.40","psRate":"31.49","week52High":346,"institutionHeld":0,"latestPrice":285.4,"eps":-1.2811130563505986,"divideRate":0,"volume":811904,"delay":0,"ttmEps":-1.2811130563505986,"open":285,"prevYearClose":163.3,"prevWeekClose":285.4,"prevMonthClose":290.8,"prevQuarterClose":290.8,"fiveDayClose":280.8,"twentyDayClose":259.4,"sixtyDayClose":162.6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06990\",pageSize:20,pageCount:7,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503292943","title":"《大行》招银国际下调科伦博泰(06990.HK)目标价至227.88元  评级“买入”","url":"https://stock-news.laohu8.com/highlight/detail?id=2503292943","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503292943?lang=zh_cn&edition=fundamental","pubTime":"2025-01-13 15:39","pubTimestamp":1736753940,"startTime":"0","endTime":"0","summary":"招银国际发表报告指，SKB378是科伦博泰与和铂医药共同开发的TSLP单抗，现已对外授权给Windward公司。交易价值最高可达9.7亿美元，含4,500万美元的首付款和近期付款，将以现金和 Windward母公司股权支付，科伦博泰与和铂医药将平分款项。SKB378可用于治疗哮喘、慢性阻塞性肺疾病等免疫疾病。招银国际维持科伦博泰“买入”评级。同时将公司目标价由243.38港元降至 227.88港元。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230628160655871_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230628160655871_s.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1409934/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06990"],"gpt_icon":0},{"id":"2503347136","title":"招银国际：维持科伦博泰生物-B(06990)“买入”评级 目标价227.88港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2503347136","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503347136?lang=zh_cn&edition=fundamental","pubTime":"2025-01-13 11:46","pubTimestamp":1736740019,"startTime":"0","endTime":"0","summary":"招银国际看好科伦博泰生物-B(06990)SKB264在2025年8-10亿元人民币的销售目标。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20250113/20250113114723_93605.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20250113/20250113114723_93605.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1236609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06990"],"gpt_icon":0},{"id":"2503345720","title":"国金证券：市场对医药左侧反转的重视上升 呼吸道感染上行关注相关板块","url":"https://stock-news.laohu8.com/highlight/detail?id=2503345720","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503345720?lang=zh_cn&edition=fundamental","pubTime":"2025-01-13 11:36","pubTimestamp":1736739368,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，近期国内北方和部分南方地区流感和其他呼吸道感染比例持续上升，建议密切跟踪传染病态势，重点关注体外诊断、中药和OTC、疫苗、仿制药等板块。中国药企创新实力及其成长空间还远未被资本市场所充分认知。新适应证的获批，标志着佳达修成为中国境内首个且目前唯一获批、可适用于男性的HPV疫苗。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1236600.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","LU0196878994.USD","BK0201","BK1161","BK1574","BK0183","06990","600109","BK0188","159938","BK1515","09939","BK0276","BK0012"],"gpt_icon":0},{"id":"2502336981","title":"和铂医药(02142.HK)科伦博泰(06990.HK)联合开发产品WIN378授出独家许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2502336981","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502336981?lang=zh_cn&edition=fundamental","pubTime":"2025-01-12 20:23","pubTimestamp":1736684580,"startTime":"0","endTime":"0","summary":"和铂医药－Ｂ(02142.HK) 公布，连同科伦博泰生物－Ｂ(06990.HK) 作为授权方，与Windward Bio订立独家授权协议，就授权方联合开发的抗胸腺基质淋巴细胞生成素(TSLP)单克隆抗体HBM9378/SKB378授予Windward Bio全球独家许可，以在大中华区及若干东南亚及西亚国家以外生产、开发、使用、推广、销售、许诺销售、进口及以其他方式商业化。授权方有权收取最多合共9.7亿美元预付款及里程碑付款以及占净销售额个位数到双位数百分比的分层特许权使用费。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-10 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180119144847470_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180119144847470_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1409684/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["06990","02142","LU0196878994.USD","BK1161","BK1583","BK1574"],"gpt_icon":0},{"id":"2502869737","title":"科伦博泰生物-B与Windward Bio AG就SKB378/HBM9378订立独占性许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2502869737","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502869737?lang=zh_cn&edition=fundamental","pubTime":"2025-01-10 21:47","pubTimestamp":1736516821,"startTime":"0","endTime":"0","summary":"根据许可协议的条款及条件，Windward Bio获授予SKB378/HBM9378在全球的研究、开发、生产及商业化的独家许可。根据许可协议的条款及条件，若Windward Bio近期发生控制权变更或与第三方订立分许可协议，许可方亦有资格向Windward Bio收取额外款项。许可协议将结合许可方与Windward Bio的研发、生产及商业化能力，支持SKB378/HBM9378的商业化进程，并建立有利的市场地位。许可协议的实施还将使公司能够将SKB378/HBM9378推向全球市场，最大化其商业价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501102151409861dd3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501102151409861dd3b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1161","LU0196878994.USD","02142","06990"],"gpt_icon":0},{"id":"2502863377","title":"和铂医药-B(02142)及科伦博泰(06990)与WINDWARD BIO AG就HBM9378/SKB378订立独家授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2502863377","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502863377?lang=zh_cn&edition=fundamental","pubTime":"2025-01-10 21:04","pubTimestamp":1736514297,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和铂医药-B 公布，公司及科伦博泰已与 Windward Bio AG就授权方联合开发的抗胸腺基质淋巴细胞生成素单克隆抗体HBM9378/SKB378订立独家授权协议。4500万美元的预付款及近期里程碑付款包括现金付款及Windward Bio母公司的股权。基于上述，授权协议的订立将授权方与Windward Bio 的研发、生产及商业化能力整合在一起，为HBM9378/SKB378走向商业化提供支持并确立有利市场地位。授权协议的实施亦让公司能够将HBM9378/SKB378推向全球市场，令其商业价值得到最大化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1236337.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","02142","LU1169590202.USD","LU0196878994.USD","BK4585","LU1169589451.USD","BK1583","AG","06990","BIO","BK4121","BK4210","BK1574","BK1161"],"gpt_icon":0},{"id":"2501371720","title":"招银国际：政策持续发力 看好中国医药估值反弹","url":"https://stock-news.laohu8.com/highlight/detail?id=2501371720","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501371720?lang=zh_cn&edition=fundamental","pubTime":"2025-01-08 16:34","pubTimestamp":1736325258,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，受益于海外降息以及国内宏观环境改善，医药作为高弹性行业有望在2025年跑赢市场。随着医疗设备招标大幅复苏，看好招标恢复的持续性，看好行业估值修复。国办再发文支持创新药械1月3日，国务院办公厅发布《关于全面深化药品医疗器械监管改革促进医药产业高质量发展的意见》。医疗设备招标大幅复苏，看好招标恢复的持续性根据众成数科统计，12月全国医疗器械公开招中标市场规模同比增长37%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1234865.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1583","02359","BK0250","BK1576","LU0320764599.SGD","LU1969619763.USD","BK0188","01801","LU2488822045.USD","LU1046422090.SGD","BK0028","BK1141","LU2125910500.SGD","02367","BK1207","BK0082","LU2045819591.USD","BK0175","LU0052750758.USD","01530","LU0196878994.USD","BK0185","06990","BK0010","BK1593","LU2328871848.SGD","LU2242644610.SGD","600056","LU0708995583.HKD","BK1589"],"gpt_icon":0},{"id":"2501471482","title":"【券商聚焦】招银国际指医药行业受益于海外降息以及国内宏观环境改善 有望在2025年跑赢市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2501471482","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501471482?lang=zh_cn&edition=fundamental","pubTime":"2025-01-08 15:41","pubTimestamp":1736322113,"startTime":"0","endTime":"0","summary":"近期，中国创新药出海交易继续快速增长，例如信达生物和恒瑞医药分别与罗氏和IDEAYA Biosciences达成了关于DLL3ADC的海外授权交易，交易总额均超过10亿美金。该行认为，受益于海外降息以及国内宏观环境改善，医药作为高弹性行业有望在2025年跑赢市场。","market":"sg","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1951004","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02359","06990","06160","01530","BK1588","BK1593","LU2125910500.SGD","BK1583","LU2328871848.SGD","BK1576","LU0708995583.HKD","LU2045819591.USD","BK1161","LU0052750758.USD","BK1589","LU2488822045.USD","LU0320764599.SGD","HK0000934320.USD","BK1141","01801","LU1046422090.SGD","LU0196878994.USD","LU0588546209.SGD","LU2242644610.SGD","BK1500","LU1969619763.USD","02367","BK1207","LU0307460666.USD"],"gpt_icon":0},{"id":"2501836077","title":"科伦博泰生物(06990.HK)核心产品博度曲妥珠单抗新药申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2501836077","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501836077?lang=zh_cn&edition=fundamental","pubTime":"2025-01-07 23:01","pubTimestamp":1736262060,"startTime":"0","endTime":"0","summary":"科伦博泰生物－Ｂ(06990.HK) 公布，靶向人类表皮生长因子受体2(HER2)的抗体药物偶联物(ADC)博度曲妥珠单抗的新药申请已获中国国家药品监督管理局药品审评中心受理，用于既往至少接受过一种抗HER2治疗的HER2阳性不可切除或转移性乳腺癌成人患者的治疗。博度曲妥珠单抗是公司研发的创新HER2 ADC。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-01-07 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230904161537733_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230904161537733_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1408574/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2501271833","title":"科伦博泰生物-B(06990)：核心产品博度曲妥珠单抗的新药申请获国家药监局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2501271833","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501271833?lang=zh_cn&edition=fundamental","pubTime":"2025-01-07 18:58","pubTimestamp":1736247515,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科伦博泰生物-B 发布公告，靶向人类表皮生长因子受体2的抗体药物偶联物博度曲妥珠单抗的新药申请(该申请)已获中国国家药品监督管理局药品审评中心受理，用于既往至少接受过一种抗HER2治疗的HER2阳性不可切除或转移性乳腺癌成人患者的治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1234496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06990","LU0196878994.USD"],"gpt_icon":0},{"id":"2501829224","title":"国联证券2025年医药生物投资策略：增量看空间 存量看结构","url":"https://stock-news.laohu8.com/highlight/detail?id=2501829224","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501829224?lang=zh_cn&edition=fundamental","pubTime":"2025-01-07 16:13","pubTimestamp":1736237583,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国联证券发布研报称，展望2025年医药生物行业，从增量上看，需关注医保、自费和出海三大空间长期发展；存量上看，则需要关注医药与医疗回归本质。全球TOP20药企的销售额前100的品种专利期还有5年的只占31%，需求确定，国内IND品种数量和质量都具备出海的基础，有望延续授权引出的趋势；其二，左侧资产的估值修复。投资建议：高质量创新药出海及左侧资产修复2025年关注两条核心投资主线：高质量创新药出海。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1234328.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","000808.SH","LU0348783233.USD","LU1794554557.SGD","LU0417516571.SGD","LU0348784397.USD","BK1574","IE00B543WZ88.USD","01801","601456","LU0196878994.USD","163118","BK1564","BK1147","LU1969619763.USD","BK0276","LU2328871848.SGD","BK1583","06990","LU1720050803.USD","01456","IE00BPRC5H50.USD","09926","IE00B5MMRT66.SGD","BK1589","LU2488822045.USD"],"gpt_icon":0},{"id":"2501047884","title":"国金证券：重磅政策出炉创新仍是最重要方向 医药健康行业进入业绩窗口关注反转预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2501047884","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501047884?lang=zh_cn&edition=fundamental","pubTime":"2025-01-06 15:56","pubTimestamp":1736150187,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，国金证券发布研报称，创新是2025医药产业投资的最大政策利好方向。医疗服务及消费医疗：医保监管促进行业可持续发展，固生堂业务版图快速拓展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1233751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0183","BK0188","BK1161","BK0276","BK0201","BK0028","LU0196878994.USD","06990","600109"],"gpt_icon":0},{"id":"1102898989","title":"异动解读 | 注射液上市获批 科伦博泰生物-B盘中大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102898989","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102898989?lang=zh_cn&edition=fundamental","pubTime":"2025-01-02 10:22","pubTimestamp":1735784542,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B(06990)今日盘中大涨5.02%,引起了市场的广泛关注。\n\n消息面上,公司发布公告称,其用于治疗复发或转移性鼻咽癌的创新药物塔戈利单抗注射液(科泰莱)已获国家药品监督管理局批准在中国上市。这一阶段性里程碑事件反映了公司在医药创新领域的进展,为鼻咽癌患者提供了新的治疗选择方案。\n\n塔戈利单抗是一种人源化单克隆抗体,可特异性结合细胞程序性死亡配体-1,阻断其与程序性死亡受体-1的相互作用,从而恢复免疫细胞对肿瘤细胞的抑制作用。该品种上市前景广阔,有望为公司创造新的利润增长点。市场对此表示了积极评价,导致公司股价在盘中出现明显上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06990"],"gpt_icon":0},{"id":"2500964582","title":"科伦博泰生物-B盘中异动 早盘股价大涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2500964582","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500964582?lang=zh_cn&edition=fundamental","pubTime":"2025-01-02 10:20","pubTimestamp":1735784403,"startTime":"0","endTime":"0","summary":"2025年01月02日早盘10时20分，科伦博泰生物-B股票出现波动，股价急速上涨5.02%。截至发稿，该股报171.500港元/股，成交量15.354万股，换手率0.12%，振幅6.55%。科伦博泰生物-B股票所在的生物技术行业中，整体跌幅为0.72%。科伦博泰生物-B公司简介：四川科伦博泰生物医药股份有限公司是一家主要从事创新药业务的研发、生产和销售的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102102004a2122fbb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250102102004a2122fbb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2500961859","title":"【港股通】科伦博泰生物-B逆市升逾4% 抗PD-L1塔戈利单抗获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2500961859","media":"金吾资讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500961859?lang=zh_cn&edition=fundamental","pubTime":"2025-01-02 09:52","pubTimestamp":1735782765,"startTime":"0","endTime":"0","summary":"金吾财讯 | 科伦博泰生物-B 早盘股价逆市走高，截至发稿，报170港元，涨4.1%，成交额927.09万港元。消息面上，公司发布公告，公司用于治疗既往接受过2线及以上化疗失败的复发或转移性鼻咽癌患者的靶向程序性细胞死亡配体1的创新人源化单克隆抗体塔戈利单抗（科泰莱）已获中国国家药品监督管理局批准于中国上市。同时，塔戈利单抗具有可管理的安全性，3级免疫相关不良事件为3.9%，未观察到3级以上免疫相关不良事件。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010209531598583bb1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025010209531598583bb1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","07226","HSCEI","BK1161","HSTECH","LU0196878994.USD"],"gpt_icon":0},{"id":"2500108969","title":"【港股异动 | 科伦博泰生物-B(06990.HK)现涨超4% 】科伦博泰生物-B(06990.HK)早盘涨超4%，截至发稿，涨4.53%，报170.7港元，成交额944.08万港元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2500108969","media":"金融界","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500108969?lang=zh_cn&edition=fundamental","pubTime":"2025-01-02 09:52","pubTimestamp":1735782730,"startTime":"0","endTime":"0","summary":"科伦博泰生物-B(06990.HK)早盘涨超4%，截至发稿，涨4.53%，报170.7港元，成交额944.08万港元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/02095247024879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["06990","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2500695579","title":"港股异动 | 科伦博泰生物-B(06990)现涨超4% 国家药监局批准塔戈利单抗注射液上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2500695579","media":"智通财经","labels":["productRelease","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500695579?lang=zh_cn&edition=fundamental","pubTime":"2025-01-02 09:46","pubTimestamp":1735782382,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物-B早盘涨超4%，截至发稿，涨4.53%，报170.7港元，成交额944.08万港元。消息面上，科伦博泰生物发布公告，公司用于治疗既往接受过2线及以上化疗失败的复发或转移性鼻咽癌患者的靶向程序性细胞死亡配体1的创新人源化单克隆抗体塔戈利单抗(科泰莱)已获国家药监局批准于中国上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1232249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 科伦博泰生物-B(06990)现涨超4% 国家药监局批准塔戈利单抗注射液上市","news_tag":"productRelease,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06990","BK1161","LU0196878994.USD"],"gpt_icon":0},{"id":"2500988151","title":"年度盘点｜2024年的港股医药生物公司跌多涨少，涨跌幅最大前十公司分别有何共性","url":"https://stock-news.laohu8.com/highlight/detail?id=2500988151","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500988151?lang=zh_cn&edition=fundamental","pubTime":"2025-01-01 18:21","pubTimestamp":1735726876,"startTime":"0","endTime":"0","summary":"刚刚过去的2024年，港股医药生物市场中的106只个股，股价（后复权）累计实现上涨的有26只，占比约25%。这里的医药生物市场，囊括了化学制药、中药、生物制品、医药商业、医疗器械、医疗服务这些细分市场。从涨幅最大或者跌幅最大的前十只个股来看，均以18A药企（港交所18A规则上市的公司）为主。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202501013284563250.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501013284563250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01681","LU0196878994.USD","01541","06996","09995","LU2488822045.USD","BK1100","YANG","BK1583","IE00B5MMRT66.SGD","BK1515","HSCEI","LU2328871848.SGD","02877","06185","07226","02415","09886","LU1969619763.USD","06855","IE00B543WZ88.USD","06990","BK1587","01952","02407","BK1574","LU1720050803.USD","BK1142","09926","09877","09939","02511","02257","BK1189","BK1585","BK1191","06998","BK1606","IE00BPRC5H50.USD","LU0417516571.SGD","02171","BK1161","LU1794554557.SGD","01167","HSTECH","BK1247","LU0348783233.USD","LU0348784397.USD","03933"],"gpt_icon":0},{"id":"2500612310","title":"全球首款CLDN18.2靶向药国内获批上市，热门靶点竞争格局几何","url":"https://stock-news.laohu8.com/highlight/detail?id=2500612310","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500612310?lang=zh_cn&edition=fundamental","pubTime":"2025-01-01 00:02","pubTimestamp":1735660967,"startTime":"0","endTime":"0","summary":"12月31日，国家药品监督管理局官网显示，安斯泰来申报的进口新药注射用佐妥昔单抗（商品名：威络益）上市，用于局部晚期不可切除或转移性胃或胃食管交界处（GEJ）腺癌患者的一线治疗。佐妥昔单抗是一款靶向治疗药物，为安斯泰来自主研发的全球首款CLDN18.2的IgG1单抗。该药物通过特异性结合CLDN18.2，增强免疫系统对肿瘤细胞的识别和攻击，从而抑制肿瘤生长。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202501013284293845.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202501013284293845.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0196878994.USD","06990","06628","BK1587","BK1589","LU2488822045.USD","LU1969619763.USD","02171","BK1161","BK1574","BK1585","LU2328871848.SGD","01801","BK1583"],"gpt_icon":0},{"id":"2495182616","title":"科伦博泰(06990.HK)抗PD-L1塔戈利单抗获国家药监局批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2495182616","media":"阿斯达克财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2495182616?lang=zh_cn&edition=fundamental","pubTime":"2024-12-31 22:04","pubTimestamp":1735653840,"startTime":"0","endTime":"0","summary":"科伦博泰生物－Ｂ(06990.HK) 公布，公司用于治疗既往接受过2线及以上化疗失败的复发或转移性鼻咽癌患者的靶向程序性细胞死亡配体1(PD-L1)创新人源化单克隆抗体塔戈利单抗(科泰莱)已获中国国家药品监督管理局批准上市。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-12-31 12:25。)AASTOCKS新闻","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220210100852532_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1407173/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["LU0196878994.USD","BK1161","06990"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":7,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06990\",params:#limit:5,,,undefined,":[{"date":"2025-03-24","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1742779800000,"name":null,"time":"盘后","dateTimestamp":1742745600000,"actualEps":null},{"date":"2024-08-19","symbol":"06990","type":"earning","reportTimeType":"post","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724031000000,"name":null,"time":"盘后","dateTimestamp":1723996800000,"actualEps":null},{"date":"2024-03-25","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1711330200000,"name":null,"time":"","dateTimestamp":1711296000000,"actualEps":null},{"date":"2023-08-28","symbol":"06990","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693186200000,"name":null,"time":"","dateTimestamp":1693152000000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06990\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06990\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2941,"buy":0.7059,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.7059,"analysts":17,"updateTime":1744646400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06990\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06990","date":"2025-04-17","current":-228.611836,"percent":0.03653,"low":-257.850518,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"high":-21.029201,"avg":-97.473315,"sd":62.021902,"marketCap":64862287200},"quantilePoints":[{"date":"2023-07-14","current":-21.13661,"twenty":-21.950454,"median":-21.915957,"eighty":-21.591449,"marketCap":14244687534},{"date":"2023-07-21","current":-23.970152,"twenty":-21.950454,"median":-21.798359,"eighty":-21.186829,"marketCap":16079230625},{"date":"2023-07-28","current":-25.171471,"twenty":-24.928642,"median":-21.953758,"eighty":-21.326081,"marketCap":16867005011},{"date":"2023-08-04","current":-23.795235,"twenty":-24.81024,"median":-23.425444,"eighty":-21.637654,"marketCap":15971316326},{"date":"2023-08-11","current":-25.354634,"twenty":-24.81024,"median":-23.323535,"eighty":-21.856149,"marketCap":16921892522},{"date":"2023-08-18","current":-27.290696,"twenty":-25.136334,"median":-23.811022,"eighty":-21.920213,"marketCap":18083628667},{"date":"2023-08-25","current":-27.955027,"twenty":-25.91111,"median":-24.066367,"eighty":-21.957062,"marketCap":18532979440},{"date":"2023-09-01","current":-41.23344,"twenty":-27.36684,"median":-24.766756,"eighty":-21.989236,"marketCap":16768455673},{"date":"2023-09-08","current":-41.179226,"twenty":-40.625811,"median":-24.994187,"eighty":-22.159386,"marketCap":16549260174},{"date":"2023-09-15","current":-42.756679,"twenty":-41.200358,"median":-25.354634,"eighty":-22.761005,"marketCap":17316444421},{"date":"2023-09-22","current":-42.808543,"twenty":-42.12743,"median":-25.915972,"eighty":-23.169807,"marketCap":17261645546},{"date":"2023-09-29","current":-41.568511,"twenty":-42.347449,"median":-27.197776,"eighty":-23.343916,"marketCap":16790375223},{"date":"2023-10-06","current":-41.914184,"twenty":-42.346401,"median":-27.481057,"eighty":-23.57336,"marketCap":16921892522},{"date":"2023-10-13","current":-45.021843,"twenty":-42.393899,"median":-34.166325,"eighty":-23.80155,"marketCap":18149387317},{"date":"2023-10-20","current":-39.509362,"twenty":-42.529229,"median":-40.304828,"eighty":-23.874674,"marketCap":15902633452},{"date":"2023-10-27","current":-41.923505,"twenty":-42.45246,"median":-40.317099,"eighty":-23.977981,"marketCap":16867093648},{"date":"2023-11-03","current":-44.17615,"twenty":-43.157759,"median":-40.968576,"eighty":-24.032126,"marketCap":17820594068},{"date":"2023-11-10","current":-48.451746,"twenty":-43.729096,"median":-41.213927,"eighty":-24.147781,"marketCap":19541278735},{"date":"2023-11-17","current":-48.422639,"twenty":-44.163404,"median":-41.246315,"eighty":-24.349478,"marketCap":19705675360},{"date":"2023-11-24","current":-47.973827,"twenty":-44.628759,"median":-41.529173,"eighty":-24.780872,"marketCap":19683755810},{"date":"2023-12-01","current":-50.941262,"twenty":-45.174782,"median":-41.90853,"eighty":-24.844962,"marketCap":20987969029},{"date":"2023-12-08","current":-50.880899,"twenty":-46.685504,"median":-41.9817,"eighty":-24.922954,"marketCap":20878371279},{"date":"2023-12-15","current":-53.058458,"twenty":-47.438439,"median":-42.172758,"eighty":-25.124621,"marketCap":21897630350},{"date":"2023-12-22","current":-55.272951,"twenty":-48.26932,"median":-42.355666,"eighty":-25.208104,"marketCap":22796331896},{"date":"2023-12-29","current":-54.398289,"twenty":-48.483234,"median":-42.389893,"eighty":-25.318001,"marketCap":22555216847},{"date":"2024-01-05","current":-54.305497,"twenty":-48.692055,"median":-42.518207,"eighty":-25.505631,"marketCap":22357940898},{"date":"2024-01-12","current":-58.852865,"twenty":-49.706536,"median":-42.808543,"eighty":-25.777515,"marketCap":24243022189},{"date":"2024-01-19","current":-48.649703,"twenty":-50.614438,"median":-43.44751,"eighty":-25.920835,"marketCap":20012549058},{"date":"2024-01-26","current":-45.202208,"twenty":-50.432693,"median":-43.523908,"eighty":-26.320623,"marketCap":18522019665},{"date":"2024-02-02","current":-38.832469,"twenty":-50.323187,"median":-43.65215,"eighty":-26.948338,"marketCap":15891673677},{"date":"2024-02-09","current":-43.972121,"twenty":-49.706536,"median":-43.780393,"eighty":-27.253528,"marketCap":18083628667},{"date":"2024-02-16","current":-51.156498,"twenty":-50.095577,"median":-43.99523,"eighty":-27.328768,"marketCap":21042767904},{"date":"2024-02-23","current":-57.052501,"twenty":-50.855188,"median":-44.095348,"eighty":-27.575851,"marketCap":23344320643},{"date":"2024-03-01","current":-55.517903,"twenty":-51.144997,"median":-44.174132,"eighty":-27.979787,"marketCap":22730573246},{"date":"2024-03-08","current":-62.556972,"twenty":-52.587613,"median":-44.308071,"eighty":-30.229554,"marketCap":25623953833},{"date":"2024-03-15","current":-80.340969,"twenty":-54.14227,"median":-44.794506,"eighty":-38.844663,"marketCap":32879324850},{"date":"2024-03-22","current":-87.812662,"twenty":-54.39157,"median":-45.089055,"eighty":-38.957109,"marketCap":35904222736},{"date":"2024-03-28","current":-54.646477,"twenty":-54.498503,"median":-45.202208,"eighty":-39.211798,"marketCap":33975302345},{"date":"2024-04-05","current":-48.790889,"twenty":-54.557693,"median":-45.399289,"eighty":-39.390336,"marketCap":30314737511},{"date":"2024-04-12","current":-51.407626,"twenty":-54.48688,"median":-46.006494,"eighty":-39.95604,"marketCap":31958703754},{"date":"2024-04-19","current":-48.134373,"twenty":-54.430626,"median":-46.386128,"eighty":-40.284427,"marketCap":29898266063},{"date":"2024-04-26","current":-71.709655,"twenty":-54.881886,"median":-46.751052,"eighty":-40.312191,"marketCap":36824843832},{"date":"2024-05-03","current":-70.050704,"twenty":-55.277405,"median":-46.894686,"eighty":-40.440284,"marketCap":35948061836},{"date":"2024-05-10","current":-80.537958,"twenty":-55.535893,"median":-47.299854,"eighty":-40.706984,"marketCap":41427949311},{"date":"2024-05-17","current":-72.846762,"twenty":-56.640749,"median":-47.434905,"eighty":-40.885351,"marketCap":37416671679},{"date":"2024-05-24","current":-76.490072,"twenty":-57.838988,"median":-47.480121,"eighty":-41.121673,"marketCap":39198277014},{"date":"2024-05-31","current":-74.804992,"twenty":-59.45269,"median":-48.0541,"eighty":-41.186166,"marketCap":38373753847},{"date":"2024-06-07","current":-77.551054,"twenty":-62.567703,"median":-48.422639,"eighty":-41.217553,"marketCap":39733102851},{"date":"2024-06-14","current":-71.048454,"twenty":-63.220056,"median":-48.609184,"eighty":-41.232055,"marketCap":36368156956},{"date":"2024-06-21","current":-75.38559,"twenty":-65.709636,"median":-48.654461,"eighty":-41.23344,"marketCap":38507460307},{"date":"2024-06-28","current":-72.361795,"twenty":-70.050704,"median":-48.790889,"eighty":-41.25919,"marketCap":36947551614},{"date":"2024-07-05","current":-71.32983,"twenty":-70.110492,"median":-48.913989,"eighty":-41.293743,"marketCap":36412725776},{"date":"2024-07-12","current":-64.338068,"twenty":-69.786991,"median":-49.290918,"eighty":-41.483815,"marketCap":32891789012},{"date":"2024-07-19","current":-64.816339,"twenty":-69.10708,"median":-50.290098,"eighty":-41.560643,"marketCap":33136917521},{"date":"2024-07-26","current":-64.836994,"twenty":-68.943217,"median":-50.396598,"eighty":-41.836002,"marketCap":33270623980},{"date":"2024-08-02","current":-67.177788,"twenty":-68.832021,"median":-50.583009,"eighty":-41.911922,"marketCap":34451697705},{"date":"2024-08-09","current":-67.337335,"twenty":-68.832021,"median":-50.91108,"eighty":-41.921641,"marketCap":34763679444},{"date":"2024-08-16","current":-69.468586,"twenty":-68.832021,"median":-51.098991,"eighty":-41.970061,"marketCap":35877899939},{"date":"2024-08-23","current":-143.952492,"twenty":-69.519081,"median":-51.282062,"eighty":-42.023931,"marketCap":36568716645},{"date":"2024-08-30","current":-142.905377,"twenty":-70.543671,"median":-51.775379,"eighty":-42.069838,"marketCap":36546432236},{"date":"2024-09-06","current":-147.713941,"twenty":-71.622574,"median":-52.451442,"eighty":-42.229208,"marketCap":37794359190},{"date":"2024-09-13","current":-159.71572,"twenty":-72.235174,"median":-53.058458,"eighty":-42.319371,"marketCap":40758185707},{"date":"2024-09-20","current":-153.295015,"twenty":-72.624329,"median":-53.663008,"eighty":-42.346401,"marketCap":39354267883},{"date":"2024-09-27","current":-152.378595,"twenty":-73.54444,"median":-54.299669,"eighty":-42.364187,"marketCap":39354267883},{"date":"2024-10-04","current":-188.785359,"twenty":-74.133327,"median":-54.381491,"eighty":-42.385888,"marketCap":48535444762},{"date":"2024-10-10","current":-168.292174,"twenty":-74.96999,"median":-54.488817,"eighty":-42.420555,"marketCap":42986626697},{"date":"2024-10-18","current":-169.261982,"twenty":-75.395206,"median":-54.742682,"eighty":-42.48514,"marketCap":43008911107},{"date":"2024-10-25","current":-173.131782,"twenty":-76.300948,"median":-55.181976,"eighty":-42.60999,"marketCap":43989425142},{"date":"2024-11-01","current":-155.135166,"twenty":-77.964709,"median":-55.298647,"eighty":-42.767052,"marketCap":39443405523},{"date":"2024-11-08","current":-154.553256,"twenty":-78.843611,"median":-55.532894,"eighty":-42.819467,"marketCap":38997717325},{"date":"2024-11-15","current":-143.716763,"twenty":-80.792913,"median":-56.569783,"eighty":-42.897746,"marketCap":35989321988},{"date":"2024-11-22","current":-149.571879,"twenty":-86.542136,"median":-57.071537,"eighty":-43.077872,"marketCap":37437808632},{"date":"2024-11-29","current":-163.214034,"twenty":-139.660525,"median":-57.926605,"eighty":-43.27892,"marketCap":40825038936},{"date":"2024-12-06","current":-164.492389,"twenty":-143.07608,"median":-58.601892,"eighty":-43.427612,"marketCap":41047883035},{"date":"2024-12-13","current":-167.859925,"twenty":-143.961595,"median":-59.46824,"eighty":-43.489321,"marketCap":41805552972},{"date":"2024-12-20","current":-160.518216,"twenty":-146.054141,"median":-61.493522,"eighty":-43.569737,"marketCap":39799956081},{"date":"2024-12-27","current":-154.616488,"twenty":-147.398806,"median":-62.556972,"eighty":-43.707223,"marketCap":38306900618},{"date":"2025-01-03","current":-146.467928,"twenty":-147.580179,"median":-62.909234,"eighty":-43.769457,"marketCap":36323588137},{"date":"2025-01-10","current":-149.189796,"twenty":-147.713941,"median":-63.270129,"eighty":-43.89543,"marketCap":36858413974},{"date":"2025-01-17","current":-146.545949,"twenty":-148.128618,"median":-63.821936,"eighty":-43.999852,"marketCap":36234450497},{"date":"2025-01-24","current":-151.096908,"twenty":-148.795989,"median":-64.223738,"eighty":-44.022873,"marketCap":37593799501},{"date":"2025-01-28","current":-144.751587,"twenty":-148.750633,"median":-64.3181,"eighty":-44.025895,"marketCap":36203787461},{"date":"2025-02-07","current":-162.755483,"twenty":-148.864023,"median":-64.816339,"eighty":-44.095348,"marketCap":40476425278},{"date":"2025-02-14","current":-166.856795,"twenty":-150.654332,"median":-65.202788,"eighty":-44.112421,"marketCap":41476404342},{"date":"2025-02-21","current":-194.414734,"twenty":-151.676932,"median":-65.382992,"eighty":-44.172115,"marketCap":48498984584},{"date":"2025-02-28","current":-211.14481,"twenty":-152.24965,"median":-65.712478,"eighty":-44.17615,"marketCap":52498900839},{"date":"2025-03-07","current":-225.41295,"twenty":-152.905086,"median":-66.309677,"eighty":-44.219461,"marketCap":56271549124},{"date":"2025-03-14","current":-227.151092,"twenty":-153.295015,"median":-66.812487,"eighty":-44.308071,"marketCap":56726085062},{"date":"2025-03-21","current":-236.708664,"twenty":-154.553256,"median":-67.337335,"eighty":-44.550078,"marketCap":59089671940},{"date":"2025-03-28","current":-231.805328,"twenty":-155.61149,"median":-67.803663,"eighty":-44.648429,"marketCap":66180441600},{"date":"2025-04-03","current":-246.46154,"twenty":-156.727441,"median":-67.952396,"eighty":-44.882152,"marketCap":70225812000},{"date":"2025-04-11","current":-242.489155,"twenty":-158.779779,"median":-68.515098,"eighty":-45.005591,"marketCap":68634936000},{"date":"2025-04-17","current":-228.611836,"twenty":-159.44307,"median":-68.80487,"eighty":-45.06217,"marketCap":64862287200}],"updateTime":1745219899091}}}